AdvancedDx Biological Laboratories USA Inc., part of ABL Diagnostics, a Euronext-listed company focused on developing molecular biology assays and software for microbiology labs, has announced a new co-marketing agreement. This partnership will jointly promote Next Generation Sequencing (NGS) solutions across the USA, integrating AdvancedDx’s DeepChek® assays and software with Complete Genomics’ DNBSEQ™ genetic sequencing platforms for microbiology laboratories nationwide.
The collaboration will enable microbiology labs to access end-to-end NGS-based solutions, offering robust and innovative assays, sequencing systems, and downstream analysis software for a variety of applications. These include, but are not limited to, HIV, viral hepatitis (HBV/HCV/HDV), respiratory viruses (such as Influenza, SARS-CoV-2, and RSV), CMV, HSV, BKV, and Tuberculosis.
Dimitri Gonzalez, Head of Diagnostics at ABL Diagnostics, expressed enthusiasm about the partnership, stating, “We are thrilled to combine our efforts to provide comprehensive solutions utilizing the latest sequencing technologies to microbiology genotyping laboratories in the USA. This agreement comes at a crucial time, as the NGS market, which was valued at USD 1.42 billion in 2022, is projected to grow at a compound annual growth rate of 13.16%.
Radoje Drmanac, Founder and Chief Scientific Officer at Complete Genomics, also shared his excitement, saying, “We are pleased to collaborate with ABL to offer a wide range of NGS-based infectious disease assays to microbiology labs. Our low-throughput sequencing platforms, including the DNBSEQ-E25 and DNBSEQ-G99, provide exceptional speed, portability, user-friendliness, and cost advantages.”
Details regarding the specific terms of the agreement have not been disclosed.
Read More antylia scientific auction for lab supplier continues trend of private equity exits in healthcare.
